{"id":880488,"date":"2025-08-29T09:12:44","date_gmt":"2025-08-29T13:12:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/"},"modified":"2025-08-29T09:12:44","modified_gmt":"2025-08-29T13:12:44","slug":"pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/","title":{"rendered":"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MIAMI, Aug.  29, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dS75ZlmutkHhu7E4Cu1K1uBsi6uN3En4xZw0UCPs_KNG-XHn39UXUl-gBU1oXUMu6nPGAC7CIiqFJsp0C003T9C-hEFquQRQtYAlJypVjZk=\" rel=\"nofollow\" target=\"_blank\"><u>Pasithea Therapeutics Corp.<\/u><\/a> (NASDAQ: KTTA) (\u201cPasithea\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management\u2019s live presentation at the H.C. Wainwright 27<sup>th<\/sup> Annual Global Investment Conference, taking place September 8-10, 2025 in\u00a0New York City, to Monday, September 8, at 5:00 PM Eastern Time.<\/p>\n<p align=\"justify\">Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event.<\/p>\n<p align=\"justify\">Details of the presentation are now as follows:<\/p>\n<p align=\"justify\">Event: H.C. Wainwright 27<sup>th<\/sup> Annual Global Investment Conference<br \/>Date: September 8, 2025<br \/>Time: 5:00 PM ET<br \/>Location: Lotte New York Palace Hotel<br \/>Webcast: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EHCeWIDQ62amdsK94M-boLaxvzTHaUbjA-3J3xZKIyAiUHpzpp52kpERq7mBAdFN_WRwKPLfrkcWolTea7RAig5JXaTQOLATzrS3SVyeIzo59L90SY9W-sRq_-LsnVQ05wtqBcAB1uTBN5cn-VyHww==\" rel=\"nofollow\" target=\"_blank\"><u>Register<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>About Pasithea Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zJ_tAJYs1Zvloc0-CjqgydbWBaS0iVg0BHei76AFi_-HLMenTmlAbuvWjqL-kBTZk1sK4vDjEVEjoCctAhQQGfVtUgTAfNgPTJS0pm47Gk6vbNwGy9JDgo1xXMoTZd1le6oaCUjs_-Imi6o3tSEMhDrc9vkYdmT25I5ypmTO8OZiO7MFWf45UBSinAkdKS74wTPAKyezKnPf2zFxFaqUebAZSaAvS21GvnyKraDEaoyE4tLBqqvs1eqnA8t9cMxMFFEfih29hx-eTRNGh7M8xlS32txO9_a7Nb0VtlZJ4S4=\" rel=\"nofollow\" target=\"_blank\">NCT06299839<\/a>), and a Phase 1\/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zJ_tAJYs1Zvloc0-CjqgyYFeMeo4kI6-HxJGN3syzJSMK9awBaZGJQj1kiEvhvMCvIyZTHndpfRuO2EMUF0FnzsTngDsSHmDwJvSPIprZG-xwVRqGcgpcgPPdWEBcFgsg-qoOXNjfx-I-ua6u84o18UU6IZvEjCUhoJxruFSlj3TdGcOBq-Os2-GW4xMxDBWHhS6Z4ei_nVmn6xQUfCwFnHWAtXzXi5p7tOP37HEJUYmYJubNCUmbiWyccQwcl-D77OUqBihSsmKUsOTAgy9SlWpg5Thaa6zYT5Vqoe0Zbw6jXGvI372k2vS_SXku77W\" rel=\"nofollow\" target=\"_blank\">NCT06961565<\/a>).<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains statements that constitute \u201cforward-looking statements\u201d made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company\u2019s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company\u2019s Phase 1\/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company\u2019s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company\u2019s plans, assumptions, expectations, beliefs and objectives, the success of the Company\u2019s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company\u2019s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>Pasithea Therapeutics Contact<\/strong>\n      <\/p>\n<p>Patrick Gaynes<br \/>Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CqwllTmoXsfwUGjj0fvbwjII5i-9rtWOGm7Qjpky6oZbQJ0WZc46L_mkOtLtI2pl5ivFq6q_f_-RzGrB5R03BaYk8f3FFa1RTcgYn7h_NOA=\" rel=\"nofollow\" target=\"_blank\">pgaynes@pasithea.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGMxMjU0YzUtZTE2NS00MGI3LWJmYzktMTdiMWY2NmU2NWRkLTEyMjEyMzYtMjAyNS0wOC0yOS1lbg==\/tiny\/Pasithea.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) &#8212; Pasithea Therapeutics Corp. (NASDAQ: KTTA) (\u201cPasithea\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management\u2019s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in\u00a0New York City, to Monday, September 8, at 5:00 PM Eastern Time. Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. Details of the presentation are now as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 5:00 PM ETLocation: Lotte New York Palace HotelWebcast: Register About Pasithea Therapeutics Corp. Pasithea &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-880488","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) &#8212; Pasithea Therapeutics Corp. (NASDAQ: KTTA) (\u201cPasithea\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management\u2019s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in\u00a0New York City, to Monday, September 8, at 5:00 PM Eastern Time. Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. Details of the presentation are now as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 5:00 PM ETLocation: Lotte New York Palace HotelWebcast: Register About Pasithea Therapeutics Corp. Pasithea &hellip; Continue reading &quot;Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T13:12:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference\",\"datePublished\":\"2025-08-29T13:12:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\"},\"wordCount\":543,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\",\"name\":\"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=\",\"datePublished\":\"2025-08-29T13:12:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","og_description":"MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) &#8212; Pasithea Therapeutics Corp. (NASDAQ: KTTA) (\u201cPasithea\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management\u2019s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in\u00a0New York City, to Monday, September 8, at 5:00 PM Eastern Time. Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. Details of the presentation are now as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 5:00 PM ETLocation: Lotte New York Palace HotelWebcast: Register About Pasithea Therapeutics Corp. Pasithea &hellip; Continue reading \"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-29T13:12:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference","datePublished":"2025-08-29T13:12:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/"},"wordCount":543,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/","name":"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=","datePublished":"2025-08-29T13:12:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDQ5NSM3MTIyMDIzIzIyMDk2ODM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pasithea-therapeutics-updates-time-of-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=880488"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880488\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=880488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=880488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=880488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}